» Articles » PMID: 36867660

HPV Upregulates MARCHF8 Ubiquitin Ligase and Inhibits Apoptosis by Degrading the Death Receptors in Head and Neck Cancer

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2023 Mar 3
PMID 36867660
Authors
Affiliations
Soon will be listed here.
Abstract

The membrane-associated RING-CH-type finger ubiquitin ligase MARCHF8 is a human homolog of the viral ubiquitin ligases Kaposi's sarcoma herpesvirus K3 and K5 that promote host immune evasion. Previous studies have shown that MARCHF8 ubiquitinates several immune receptors, such as the major histocompatibility complex II and CD86. While human papillomavirus (HPV) does not encode any ubiquitin ligase, the viral oncoproteins E6 and E7 are known to regulate host ubiquitin ligases. Here, we report that MARCHF8 expression is upregulated in HPV-positive head and neck cancer (HNC) patients but not in HPV-negative HNC patients compared to normal individuals. The MARCHF8 promoter is highly activated by HPV oncoprotein E6-induced MYC/MAX transcriptional activation. The knockdown of MARCHF8 expression in human HPV-positive HNC cells restores cell surface expression of the tumor necrosis factor receptor superfamily (TNFRSF) death receptors, FAS, TRAIL-R1, and TRAIL-R2, and enhances apoptosis. MARCHF8 protein directly interacts with and ubiquitinates the TNFRSF death receptors. Further, MARCHF8 knockout in mouse oral cancer cells expressing HPV16 E6 and E7 augments cancer cell apoptosis and suppresses tumor growth in vivo. Our findings suggest that HPV inhibits host cell apoptosis by upregulating MARCHF8 and degrading TNFRSF death receptors in HPV-positive HNC cells.

Citing Articles

Ubiquitin and ubiquitin-like proteins in HPV-driven carcinogenesis.

Wootton L, Morgan E Oncogene. 2025; 44(11):713-723.

PMID: 40011575 PMC: 11888991. DOI: 10.1038/s41388-025-03310-6.


Understanding and treating HPV-associated oropharyngeal carcinoma: insights from a MedNewsWeek Keynote lecture by Dr Theodoros N. Teknos and literature review.

Cortiana V, Nadar S, Gambill J, Mahendru D, Theyver A, Coloma H Ther Adv Med Oncol. 2025; 17:17588359251322290.

PMID: 40008193 PMC: 11851760. DOI: 10.1177/17588359251322290.


Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use.

Zhang Y, Qiu K, Ren J, Zhao Y, Cheng P Signal Transduct Target Ther. 2025; 10(1):44.

PMID: 39856040 PMC: 11760352. DOI: 10.1038/s41392-024-02083-w.


C-71980262, a novel small molecule against human papilloma virus-16 E6 (HPV-16 E6) with anticancer potency against cervical cancer: A computational guided approach.

Kumar A Iran J Basic Med Sci. 2024; 27(11):1389-1396.

PMID: 39386235 PMC: 11459339. DOI: 10.22038/ijbms.2024.78090.16882.


Further Characterization of the Antiviral Transmembrane Protein MARCH8.

Tada T, Zhang Y, Kong D, Tanaka M, Yao W, Kameoka M Cells. 2024; 13(8.

PMID: 38667313 PMC: 11049619. DOI: 10.3390/cells13080698.


References
1.
Jones D, Thompson D, Munger K . Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology. 1998; 239(1):97-107. DOI: 10.1006/viro.1997.8851. View

2.
Ashkenazi A, Dixit V . Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999; 11(2):255-60. DOI: 10.1016/s0955-0674(99)80034-9. View

3.
Agrawal N, Frederick M, Pickering C, Bettegowda C, Chang K, Li R . Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011; 333(6046):1154-7. PMC: 3162986. DOI: 10.1126/science.1206923. View

4.
Rappsilber J, Mann M, Ishihama Y . Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc. 2007; 2(8):1896-906. DOI: 10.1038/nprot.2007.261. View

5.
Chen W, Patel D, Jia Y, Yu Z, Liu X, Shi H . MARCH8 Suppresses Tumor Metastasis and Mediates Degradation of STAT3 and CD44 in Breast Cancer Cells. Cancers (Basel). 2021; 13(11). PMC: 8196951. DOI: 10.3390/cancers13112550. View